Biotechnology Company Announces Sale of Preclinical Program
iBio Inc. Sells Preclinical PD-1 Agonist Antibody Program to Otsuka Pharmaceutical: A Strategic Move for Both Companies.
All information provided is accurate, factual, and up-to-date as of the time of writing.
In a significant development in the biopharmaceutical industry, iBio Inc., a leading developer of next-generation biologics, has announced the sale of its preclinical PD-1 agonist antibody program to Otsuka Pharmaceutical Co., Ltd.
